查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2093079

伴侶動物藥品市場－2026-2032年全球市場預測

Companion Animal Pharmaceuticals Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，伴侶動物藥品市場將成長至 320.4 億美元，複合年成長率為 7.87%。

主要市場統計數據
基準年 2025 188.5億美元
預計年份：2026年 202.8億美元
預測年份：2032年 320.4億美元
複合年成長率 (%) 7.87%

伴侶動物藥品市場趨勢正從症狀治療轉向預防性、個人化和以療效為導向的獸醫照護。寵物數量的增加、寵物「人性化」的日益普及、伴侶動物壽命的延長以及獸醫服務覆蓋範圍的擴大，都推動了驅蟲藥、感染疾病、疼痛管理、皮膚病學、心臟病學、內分泌循環系統、腫瘤學、疫苗和行為健康等領域的治療需求。雖然犬貓仍然是產品研發的重點，但馬和其他伴侶動物也持續推動對專業治療的需求成長。

寵物飼主日益成長的臨床期望、對動物福利的日益重視以及獸醫在慢性病管理中作用的不斷擴大，共同塑造了行業趨勢。同時，更嚴格的監管、對合理使用抗菌藥物的要求、強制性的藥物安全監測以及品質標準，都提高了藥物安全性、有效性、標籤和上市後監測的標準。競爭優勢越來越依賴差異化的配方、針對不同物種最佳化的劑量、偏好、長效配方、提高用藥依從性的支持以及與獸醫決策相符的循證療效聲明。

伴侶動物製藥產業的變革性變化

在醫療保健、數位獸醫和先進藥物創新融合的推動下，這一領域正經歷著變革性的變化。預防性護理不再局限於傳統的疫苗接種和寄生蟲防治，而是擴展到包含診斷、風險評估和定期治療計劃的綜合健康方案。這種轉變使得對骨關節炎、異位性皮膚炎、糖尿病、腎臟病、心臟病和肥胖相關疾病等慢性疾病進行早期療育成為可能。

人工智慧（AI）的累積影響

人工智慧 (AI) 透過改善藥物發現、開發、臨床運作、商業化和上市後監測，對整個伴侶動物製藥領域產生了累積的影響。在藥物發現方面，AI 驅動的建模能夠識別治療標靶、篩檢化合物、最佳化先導化合物，甚至預測跨物種的藥物動力學和毒理學特性。這些能力在獸醫領域尤其重要，因為物種差異、品種特異性風險和劑量需求的變化往往會使藥物開發變得複雜。

關鍵區域洞察

在亞太地區，尤其是在中國、印度、日本、韓國和澳大利亞，寵物市場正受到都市區寵物擁有增加、可支配收入成長以及人們對常規獸醫護理接受度提高等因素的影響。隨著家庭對伴侶動物醫療保健的需求日益成長，該地區對預防性驅蟲、疫苗、皮膚病治療和慢性病治療的需求仍然強勁。不同地區的法律規範、獸醫基礎設施以及獲得高品質治療的途徑存在顯著差異，這為開發區域性配方、透過教育推廣以及建立經銷夥伴關係創造了機會。

來自關鍵群體的見解

在東協，隨著都市化、公寓化和寵物「人性化」的推進，以及人們對醫療保健期望的改變，伴侶動物藥品的重要性日益凸顯。儘管新加坡、泰國、馬來西亞、印尼、越南和菲律賓等市場在獸醫保健基礎設施和監管方面的成熟度有所不同，但人們對預防醫學、寄生蟲控制、疫苗接種以及皮膚病和營養治療日益成長的興趣，支撐了市場對伴侶動物藥品的廣泛需求。當地經銷商的能力、與獸醫的合作以及氣候相關疾病的教育，是市場成功的關鍵。

主要國家概況

美國是伴侶動物藥品的主要市場，這得益於其先進的獸醫實踐、完善的高水平獸醫專科護理、廣泛的預防醫學以及診斷技術的廣泛應用。加拿大也呈現類似的市場需求模式，尤其注重預防醫學、寄生蟲控制、疼痛管理和慢性病治療，並擁有高標準的藥物安全性和獸醫監管系統。在墨西哥，由於寵物數量的增加、都市區獸醫醫院的擴張以及對疫苗、驅蟲藥和便捷治療藥物需求的成長，該市場正蓬勃發展。

業界領導者使用的實用建議

產業領導者應優先考慮基於實證醫學的差異化，開發能夠滿足未被滿足的需求、提高用藥依從性並顯著改善伴侶動物生活品質的療法。製劑創新應著重於偏好、給藥便利性、長效製劑、物種適宜劑量、臨床上合理的合併製劑。生命週期策略應整合藥物安全監測、真實世界數據和獸醫回饋，以最佳化產品定位並建立信任。

調查方法

本執行摘要採用系統的二手資料研究方法檢驗，參考了經核實的公共領域和行業認可的資訊來源，包括獸醫監管機構、動物衛生機構的參考資料、同行評審的科學文獻、獸醫協會出版刊物、藥物安全研究途徑指南、抗菌藥物管理框架以及國家級動物衛生政策。分析重點關注監管趨勢、治療方案採用模式、獸醫基礎設施、疾病負擔、寵物飼養趨勢以及獸醫實踐中的技術應用等定性指標。

結論

伴侶動物藥品正邁入一個更先進的時代，其特點是人們對預防性護理、慢性病管理、數位整合以及更安全、更便捷的治療方案的需求日益成長。寵物飼主越來越期望醫療保健標準能夠體現以家庭為中心的理念，而獸醫則尋求有可靠證據支持、基於負責任的配方原則且具有實用給藥優勢的產品。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 伴侶動物藥品市場：依動物類型分類

  • 鳥
  • 貓
  • 狗
  • 馬

第8章 伴侶動物藥品市場：依產品類型分類

  • 抗生素
    • 抗生素
    • 抗真菌藥物
    • 驅蟲
  • 生物製劑
    • 干擾素
    • 單株抗體
    • 疫苗
  • 生長促效劑
  • 藥用飼料添加劑
  • 製藥

第9章 伴侶動物藥品市場：依劑型分類

  • 注射藥物
  • 液體
  • 修補
  • 粉末
  • 噴
  • 藥片

第10章 伴侶動物藥品市場：依通路分類

  • 線上零售商
  • 連鎖藥局
  • 動物診所

第11章 伴侶動物藥品市場：依疾病分類

  • 慢性病
  • 胃腸道問題
    • 結腸炎
    • 發炎性腸道疾病
  • 感染疾病
    • 細菌感染疾病
    • 病毒感染疾病

第12章 伴侶動物藥品市場：依最終用戶分類

  • 動物收容所和救援組織
  • 寵物飼養員/訓練員
  • 寵物飼主
  • 獸醫

第13章 伴侶動物藥品市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 伴侶動物藥品市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 伴侶動物藥品市場：依國家分類

  • 美國
  • 德國
  • 中國
  • 英國
  • 印度
  • 日本
  • 俄羅斯
  • 巴西
  • 加拿大
  • 義大利
  • 墨西哥
  • 法國
  • 西班牙
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Alivira Animal Health Limited
  • Ashish Life Science Pvt. Ltd.
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Chanelle Pharma
  • Dechra Pharmaceuticals PLC
  • Eco Animal Health Group PLC
  • Elanco Animal Health Incorporated
  • Endovac Animal Health, LLC
  • Hester Biosciences Limited
  • Hipra Laboratories, SA
  • Indian Immunologicals Ltd.
  • Kyoritsu Seiyaku Corporation
  • Meiji Group
  • Merck KGaA
  • Neogen Corporation
  • Norbrook Laboratories Ltd.
  • Orion Corporation
  • Phibro Animal Health Corporation
  • SkyEc Pharmaceuticals Private Limited
  • Stanex Drugs and Chemicals Pvt Ltd.
  • Tianjin Ringpu BIoTechnology Co., Ltd.
  • Veko Care
  • Vetbiolix
  • Virbac SA
  • Zoetis Inc.
  • Zydus Animal Health
Product Code: MRR-FD3F12D52B58

The Companion Animal Pharmaceuticals Market is projected to grow by USD 32.04 billion at a CAGR of 7.87% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 18.85 billion
Estimated Year [2026] USD 20.28 billion
Forecast Year [2032] USD 32.04 billion
CAGR (%) 7.87%

The companion animal pharmaceuticals landscape is evolving from episodic treatment toward preventive, personalized, and outcomes-oriented veterinary care. Rising pet ownership, increased pet humanization, longer companion animal lifespans, and broader access to veterinary services are strengthening demand for therapeutics across parasiticides, anti-infectives, pain management, dermatology, cardiology, endocrinology, oncology, vaccines, and behavioral health. Dogs and cats remain central to product development priorities, while equine and other companion species continue to support specialized therapeutic demand.

Industry momentum is being shaped by higher clinical expectations from pet owners, greater emphasis on animal welfare, and the growing role of veterinarians in chronic disease management. At the same time, regulatory scrutiny, antimicrobial stewardship requirements, pharmacovigilance obligations, and quality standards are raising the bar for drug safety, efficacy, labeling, and post-approval monitoring. Competitive advantage increasingly depends on differentiated formulations, species-specific dosing, palatability, long-acting delivery, adherence support, and evidence-based claims that align with veterinary decision-making.

Transformative Shifts in the Companion Animal Pharmaceuticals Landscape

The sector is undergoing transformative shifts driven by the convergence of preventive healthcare, digital veterinary engagement, and advanced pharmaceutical innovation. Preventive therapeutics are expanding beyond traditional vaccination and parasite control into integrated wellness protocols that combine diagnostics, risk profiling, and recurring treatment plans. This shift supports earlier intervention for chronic conditions such as osteoarthritis, atopic dermatitis, diabetes, kidney disease, heart disease, and obesity-related disorders.

Another defining change is the movement toward convenience-led drug delivery. Chewables, flavored tablets, transdermal formats, extended-release injectables, and combination therapies are gaining relevance as adherence becomes a measurable determinant of outcomes. Veterinary practices are also adopting digital reminders, teletriage, e-prescribing, and home delivery models that reshape pharmaceutical access while preserving the veterinarian's role in diagnosis and therapeutic oversight.

Regulatory and social pressures are also influencing product strategy. Antimicrobial resistance concerns are accelerating demand for responsible antibiotic use, diagnostics-supported prescribing, and alternatives such as vaccines, immunomodulators, and targeted therapies. Sustainability considerations are influencing packaging, supply chain resilience, and manufacturing practices, while pharmacovigilance data is becoming a strategic tool for lifecycle management and trust building.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative impact across companion animal pharmaceuticals by improving discovery, development, clinical operations, commercialization, and post-market surveillance. In drug discovery, AI-supported modeling can help identify therapeutic targets, screen compounds, optimize lead candidates, and predict pharmacokinetic or toxicological characteristics across species. These capabilities are especially valuable in veterinary medicine, where species differences, breed-specific risks, and variable dosing requirements can complicate development.

In clinical development, AI-enabled analytics can support protocol design, patient selection, endpoint monitoring, and real-world evidence generation. Veterinary electronic health records, diagnostic imaging, laboratory data, claims data, and wearable device inputs can help identify disease patterns and treatment-response signals when governed by robust data quality and privacy controls. AI may also strengthen pharmacovigilance by detecting adverse event patterns earlier, improving signal prioritization, and supporting more consistent safety reporting.

Commercially, AI is enhancing educational engagement with veterinarians, demand planning, inventory optimization, and adherence programs. However, the value of AI depends on validated datasets, explainable models, regulatory alignment, cybersecurity, and human oversight. In companion animal health, trust remains central: veterinarians and pet owners need transparent evidence that AI-enabled tools improve care decisions without replacing clinical judgment.

Key Regional Insights

Asia-Pacific is shaped by expanding urban pet ownership, rising disposable incomes, and increasing acceptance of routine veterinary care, particularly in China, India, Japan, South Korea, and Australia. The region shows strong demand for preventive parasiticides, vaccines, dermatology treatments, and chronic disease therapies as companion animals increasingly receive family-level healthcare attention. Regulatory pathways, veterinary infrastructure, and access to premium therapeutics vary widely, creating opportunities for localized formulations, education-led adoption, and distribution partnerships.

North America remains one of the most mature regions for companion animal pharmaceuticals, supported by high veterinary service utilization, strong pet insurance penetration relative to many other regions, established diagnostic infrastructure, and broad awareness of preventive medicine. The United States and Canada demonstrate sustained demand for advanced therapeutics addressing pain, dermatology, oncology, cardiometabolic disorders, and parasite prevention, with digital pharmacy models and clinic-integrated care plans influencing access.

Latin America is advancing through growing middle-class pet ownership, increased veterinary clinic networks, and greater adoption of vaccines, anti-parasitic products, and anti-infectives. Brazil and Mexico are particularly relevant due to large pet populations and expanding retail and veterinary channels. Affordability, counterfeit product control, cold-chain reliability, and veterinarian education remain important considerations for sustainable growth.

Europe is characterized by stringent regulatory oversight, high animal welfare standards, and strong emphasis on antimicrobial stewardship. Demand is supported by advanced veterinary care in Western Europe, while Central and Eastern Europe continue to broaden access to modern companion animal medicines. The region's policy environment encourages responsible prescribing, pharmacovigilance, and quality compliance, making evidence generation and lifecycle safety management essential.

The Middle East is developing as pet ownership rises in urban centers, especially among expatriate and affluent households. Companion animal pharmaceutical demand is linked to premium veterinary clinics, vaccination programs, parasite control, and dermatology care, while hot climates elevate the importance of ectoparasite and vector-borne disease prevention. Africa presents a more heterogeneous landscape, with companion animal health concentrated in urban markets and private veterinary settings. Access, affordability, veterinary workforce density, and import dependency influence pharmaceutical availability, while rabies control and parasite management remain critical public and animal health priorities.

Key Group Insights

ASEAN countries are becoming increasingly important for companion animal pharmaceuticals as urbanization, apartment living, and pet humanization reshape healthcare expectations. Markets such as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines differ in veterinary infrastructure and regulatory maturity, but demand is broadly supported by preventive medicine, parasite control, vaccination, and growing interest in dermatology and nutrition-linked therapeutics. Local distributor capability, veterinarian engagement, and climate-relevant disease education are key success factors.

The GCC demonstrates demand concentrated in premium veterinary services, high-income urban households, and expatriate communities. Companion animal care is influenced by climate, import-driven supply chains, and the need for reliable cold-chain logistics for vaccines and temperature-sensitive therapies. Preventive care, dermatology, parasite control, and specialized treatments are increasingly relevant as veterinary clinics expand service quality.

The European Union provides a harmonized regulatory environment with high standards for veterinary medicinal product authorization, safety monitoring, manufacturing quality, and antimicrobial responsibility. This creates predictable but demanding pathways for companion animal pharmaceuticals, where robust clinical evidence, pharmacovigilance systems, and compliant labeling are essential. EU animal welfare priorities also reinforce demand for therapies that improve quality of life in aging pets.

BRICS countries collectively represent diverse companion animal pharmaceutical dynamics. China and India are expanding rapidly through urban pet ownership and rising veterinary service demand, Brazil has a well-established pet care culture, Russia maintains demand across urban centers despite supply chain complexity, and South Africa supports a comparatively developed private veterinary sector within the African context. Across BRICS, localization, affordability, and regulatory navigation are decisive.

The G7 group reflects mature veterinary pharmaceutical environments with advanced clinical practice, strong diagnostic use, and high expectations for product evidence. The United States, Canada, Japan, Germany, France, Italy, and the United Kingdom support demand for chronic disease therapies, pain management, dermatology, oncology, and preventive care. NATO countries, many of which overlap with advanced European and North American veterinary systems, show strong emphasis on supply chain security, regulatory compliance, and pharmaceutical quality standards, particularly for cross-border distribution and essential animal health products.

Key Country Insights

The United States is a leading environment for companion animal pharmaceuticals due to high pet medicalization, advanced veterinary specialty care, strong preventive health adoption, and broad use of diagnostics. Canada shares similar demand patterns, with emphasis on preventive care, parasite control, pain management, and chronic disease treatment, supported by high standards for drug safety and veterinary oversight. Mexico is gaining traction through expanding pet ownership, urban veterinary clinics, and rising demand for vaccines, anti-parasitics, and accessible therapeutics.

Brazil has a prominent companion animal culture and strong demand for preventive pharmaceuticals, dermatology products, anti-infectives, and parasite control, supported by a broad veterinary channel structure. The United Kingdom demonstrates mature pet healthcare behavior, strong veterinary professionalism, and significant attention to antimicrobial stewardship and animal welfare. Germany is characterized by rigorous quality expectations, advanced veterinary care, and demand for evidence-backed therapies, while France shows strong demand for preventive and chronic care medicines within a regulated veterinary environment. Russia maintains companion animal pharmaceutical demand in urban centers, though logistics, registration, and supply continuity are important considerations. Italy and Spain both show sustained demand for pet healthcare, with parasite control, dermatology, pain management, and vaccines benefiting from high companion animal ownership and established veterinary services.

China is experiencing rapid companion animal healthcare development, driven by urban pet ownership, premiumization, and expanding veterinary hospital networks. India is seeing increased demand for vaccines, parasiticides, dermatology treatments, and anti-infectives as pet adoption grows in major cities, though affordability and access remain critical. Japan has an aging pet population that supports demand for geriatric care, oncology, cardiology, renal disease management, pain relief, and advanced diagnostics. Australia's companion animal pharmaceutical needs are shaped by high pet ownership, strong veterinary standards, and significant demand for parasite prevention due to regional ectoparasite and vector risks. South Korea is advancing through pet humanization, premium veterinary services, and increasing interest in chronic disease management, dermatology, and preventive healthcare.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence-based differentiation by developing therapies that address unmet veterinary needs, improve adherence, and demonstrate measurable quality-of-life benefits for companion animals. Formulation innovation should focus on palatability, ease of administration, long-acting delivery, species-appropriate dosing, and combination products where clinically justified. Lifecycle strategies should integrate pharmacovigilance, real-world evidence, and veterinarian feedback to refine positioning and support trust.

Organizations should strengthen antimicrobial stewardship by investing in diagnostics-aligned prescribing support, targeted anti-infective use, vaccines, and alternatives that reduce unnecessary antibiotic exposure. Expanding digital capabilities can improve veterinarian education, inventory planning, treatment reminders, adherence monitoring, and owner engagement, but digital tools should be clinically validated and designed to support-not replace-veterinary judgment.

Regional execution should be localized. Mature markets require robust clinical evidence, specialty education, and compliance excellence, while emerging markets need affordability strategies, reliable distribution, counterfeit prevention, and practitioner training. Supply chain resilience, cold-chain integrity, regulatory intelligence, and quality assurance should be treated as strategic priorities, especially for vaccines, biologics, and temperature-sensitive products.

Research Methodology

This executive summary is developed through a structured secondary research approach using verified public-domain and industry-recognized sources, including veterinary regulatory agencies, animal health authorities, peer-reviewed scientific literature, veterinary association publications, pharmacovigilance guidance, antimicrobial stewardship frameworks, and country-level animal health policy references. The analysis emphasizes qualitative indicators such as regulatory direction, therapeutic adoption patterns, veterinary infrastructure, disease burden relevance, pet ownership trends, and technology adoption in veterinary practice.

The methodology excludes market sizing, market share calculation, revenue estimation, and forecasting. Insights are synthesized through triangulation of credible sources to identify consistent patterns across regions, groups, and countries. Particular attention is given to companion animal therapeutic categories, veterinary prescribing behavior, product access conditions, regulatory compliance, safety monitoring, and the implications of artificial intelligence for research, clinical decision support, and post-market surveillance.

Conclusion

Companion animal pharmaceuticals are entering a more sophisticated era defined by preventive care, chronic disease management, digital integration, and demand for safer, more convenient therapies. Pet owners increasingly expect healthcare standards that mirror family-centered care, while veterinarians require products supported by strong evidence, responsible prescribing principles, and practical administration benefits.

Future competitiveness will depend on the ability to combine pharmaceutical innovation with regulatory discipline, real-world evidence, AI-enabled intelligence, and localized market execution. Organizations that improve adherence, address aging pet populations, support antimicrobial stewardship, and build resilient regional access models will be best positioned to meet the evolving needs of veterinarians, pet owners, and companion animals worldwide.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Companion Animal Pharmaceuticals Market, by Animal Type

  • 7.1. Introduction
  • 7.2. Birds
  • 7.3. Cats
  • 7.4. Dogs
  • 7.5. Horses

8. Companion Animal Pharmaceuticals Market, by Product Type

  • 8.1. Introduction
  • 8.2. Antimicrobials
    • 8.2.1. Antibiotics
    • 8.2.2. Antifungals
    • 8.2.3. Antiparasitics
  • 8.3. Biologics
    • 8.3.1. Interferons
    • 8.3.2. Monoclonal Antibodies
    • 8.3.3. Vaccines
  • 8.4. Growth Promoters
  • 8.5. Medicated Feed Additives
  • 8.6. Pharmaceutical Drugs

9. Companion Animal Pharmaceuticals Market, by Formulation

  • 9.1. Introduction
  • 9.2. Injectables
  • 9.3. Liquids
  • 9.4. Patches
  • 9.5. Powders
  • 9.6. Sprays
  • 9.7. Tablets

10. Companion Animal Pharmaceuticals Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Online Retailers
  • 10.3. Pharmacy Chains
  • 10.4. Veterinary Clinics

11. Companion Animal Pharmaceuticals Market, by Disease Condition

  • 11.1. Introduction
  • 11.2. Chronic Conditions
  • 11.3. Gastrointestinal Issues
    • 11.3.1. Colitis
    • 11.3.2. Inflammatory Bowel Disease
  • 11.4. Infectious Diseases
    • 11.4.1. Bacterial Infections
    • 11.4.2. Viral Infections

12. Companion Animal Pharmaceuticals Market, by End User

  • 12.1. Introduction
  • 12.2. Animal Shelters & Rescue Organizations
  • 12.3. Pet Breeders / Trainers
  • 12.4. Pet Owners
  • 12.5. Veterinarians

13. Companion Animal Pharmaceuticals Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Companion Animal Pharmaceuticals Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Companion Animal Pharmaceuticals Market, by Country

  • 15.1. United States
  • 15.2. Germany
  • 15.3. China
  • 15.4. United Kingdom
  • 15.5. India
  • 15.6. Japan
  • 15.7. Russia
  • 15.8. Brazil
  • 15.9. Canada
  • 15.10. Italy
  • 15.11. Mexico
  • 15.12. France
  • 15.13. Spain
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Alivira Animal Health Limited
  • 17.2. Ashish Life Science Pvt. Ltd.
  • 17.3. Boehringer Ingelheim International GmbH
  • 17.4. Ceva Sante Animale
  • 17.5. Chanelle Pharma
  • 17.6. Dechra Pharmaceuticals PLC
  • 17.7. Eco Animal Health Group PLC
  • 17.8. Elanco Animal Health Incorporated
  • 17.9. Endovac Animal Health, LLC
  • 17.10. Hester Biosciences Limited
  • 17.11. Hipra Laboratories, S.A.
  • 17.12. Indian Immunologicals Ltd.
  • 17.13. Kyoritsu Seiyaku Corporation
  • 17.14. Meiji Group
  • 17.15. Merck KGaA
  • 17.16. Neogen Corporation
  • 17.17. Norbrook Laboratories Ltd.
  • 17.18. Orion Corporation
  • 17.19. Phibro Animal Health Corporation
  • 17.20. SkyEc Pharmaceuticals Private Limited
  • 17.21. Stanex Drugs and Chemicals Pvt Ltd.
  • 17.22. Tianjin Ringpu Biotechnology Co., Ltd.
  • 17.23. Veko Care
  • 17.24. Vetbiolix
  • 17.25. Virbac S.A.
  • 17.26. Zoetis Inc.
  • 17.27. Zydus Animal Health

LIST OF FIGURES

  • FIGURE 1. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIRDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIRDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIRDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CATS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CATS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CATS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DOGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DOGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HORSES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HORSES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HORSES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIMICROBIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTIMICROBIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIFUNGALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTIFUNGALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIFUNGALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTIPARASITICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIPARASITICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTIPARASITICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INTERFERONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INTERFERONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INTERFERONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GROWTH PROMOTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GROWTH PROMOTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GROWTH PROMOTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MEDICATED FEED ADDITIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MEDICATED FEED ADDITIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MEDICATED FEED ADDITIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PHARMACEUTICAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PHARMACEUTICAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PHARMACEUTICAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INJECTABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INJECTABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LIQUIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LIQUIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LIQUIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PATCHES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PATCHES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL POWDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL POWDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL POWDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SPRAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SPRAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SPRAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ONLINE RETAILERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ONLINE RETAILERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ONLINE RETAILERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PHARMACY CHAINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PHARMACY CHAINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PHARMACY CHAINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VETERINARY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VETERINARY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL VETERINARY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CHRONIC CONDITIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CHRONIC CONDITIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CHRONIC CONDITIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GASTROINTESTINAL ISSUES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GASTROINTESTINAL ISSUES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GASTROINTESTINAL ISSUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL COLITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL COLITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL COLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ANIMAL SHELTERS & RESCUE ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANIMAL SHELTERS & RESCUE ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ANIMAL SHELTERS & RESCUE ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PET BREEDERS / TRAINERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PET BREEDERS / TRAINERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PET BREEDERS / TRAINERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PET OWNERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PET OWNERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PET OWNERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL VETERINARIANS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL VETERINARIANS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL VETERINARIANS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. GCC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. GCC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. GCC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. GCC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2032 (USD MILLION)
  • TABLE 197. GCC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 198. GCC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 199. GCC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. GCC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 201. GCC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2032 (USD MILLION)
  • TABLE 202. GCC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 203. GCC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. G7 COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 227. G7 COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. G7 COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. G7 COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2032 (USD MILLION)
  • TABLE 230. G7 COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 231. G7 COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 232. G7 COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. G7 COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 234. G7 COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2032 (USD MILLION)
  • TABLE 235. G7 COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 236. G7 COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. NATO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 238. NATO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. NATO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. NATO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2032 (USD MILLION)
  • TABLE 241. NATO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 242. NATO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 243. NATO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. NATO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 245. NATO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2032 (USD MILLION)
  • TABLE 246. NATO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 247. NATO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 261. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2032 (USD MILLION)
  • TABLE 264. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 265. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 266. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 267. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 268. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2032 (USD MILLION)
  • TABLE 269. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 270. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 293. INDIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 294. INDIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. INDIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. INDIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2032 (USD MILLION)
  • TABLE 297. INDIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 298. INDIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 299. INDIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 300. INDIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 301. INDIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2032 (USD MILLION)
  • TABLE 302. INDIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 303. INDIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 304. JAPAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 305. JAPAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. JAPAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. JAPAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2032 (USD MILLION)
  • TABLE 308. JAPAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 309. JAPAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 310. JAPAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 311. JAPAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 312. JAPAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2032 (USD MILLION)
  • TABLE 313. JAPAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 314. JAPAN COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 315. RUSSIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 316. RUSSIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. RUSSIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. RUSSIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2032 (USD MILLION)
  • TABLE 319. RUSSIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 320. RUSSIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 321. RUSSIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 322. RUSSIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 323. RUSSIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2032 (USD MILLION)
  • TABLE 324. RUSSIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 325. RUSSIA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 326. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 327. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 328. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2032 (USD MILLION)
  • TABLE 330. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 331. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 332. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION